Variant position: 163 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 261 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human YGYSYMPSGAYVYPPPVANG MYPCPPGYPYPPPPPEFYPGP
Mouse YGYPYMPSGAYVFPPPVANG MYPCPPGYPYPPPPPEFYPGP
Rat YGYPYMPSGAYVFPPPVANG MYPCPPGYPYPPPPPEFYPGP
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 261 WW domain-binding protein 2
146 – 255 Pro-rich
133 – 177 Missing. In isoform 2.
143 – 143 Y -> F. No effect on phosphorylation induced by EGF.
145 – 145 Y -> F. No effect on phosphorylation induced by EGF.
153 – 153 Y -> F. No effect on phosphorylation induced by EGF.
164 – 164 Y -> F. No effect on phosphorylation induced by EGF.
170 – 170 Y -> F. No effect on phosphorylation induced by EGF.
172 – 172 Y -> F. No effect on phosphorylation induced by EGF.
180 – 180 Y -> F. No effect on phosphorylation induced by EGF.
Wbp2 is required for normal glutamatergic synapses in the cochlea and is crucial for hearing.
Buniello A.; Ingham N.J.; Lewis M.A.; Huma A.C.; Martinez-Vega R.; Varela-Nieto I.; Vizcay-Barrena G.; Fleck R.A.; Houston O.; Bardhan T.; Johnson S.L.; White J.K.; Yuan H.; Marcotti W.; Steel K.P.;
EMBO Mol. Med. 8:191-207(2016)
Cited for: INVOLVEMENT IN DFNB107; VARIANTS DFNB107 THR-160; LEU-163 AND VAL-224;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.